Researchers at the UC San Diego Center for Microbiome Innovation (CMI), the world’s leading microbiome research organization, have expanded their Panasas® high-performance computing (HPC) storage infrastructure with an additional two petabytes of ActiveStor® data storage […]
The recently published Clinical Practice Guidelines on the role of probiotics in the management of gastrointestinal disorders by the American Gastroenterological Association (AGA) contains some points of discussion, celebration, and contention for the probiotic field. […]
US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost’s USD 5 million series A equity round as well as a joint development […]
Novozymes announced that it has acquired PrecisionBiotics Group Limited. Based in Cork, Ireland, PrecisionBiotics Group holds a leading position within probiotics for human gut health and is well positioned with several clinically backed products already […]
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today announces a new financing totaling €46.3 million ($52.6million) to progress the clinical development of its therapeutic […]
The role genetics and gut bacteria play in human health has long been a fruitful source of scientific enquiry, but new research marks a significant step forward in unraveling this complex relationship. Its findings could […]
An article has been published in Frontiers in Medicine: Regulatory Science section, which proposes a new set of recommendations for addressing the various regulatory and technical challenges when assessing the safety of Live Biotherapeutic Products […]
Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborated to bring OMNImet™·GUT, the first device for in-home collection and ambient-temperature storage and shipping of […]
Two of the most important and largest microbiome studies ever undertaken in patients with chronic inflammatory bowel disease have been conducted by a team of researchers in Cork from APC Microbiome Ireland. The research, which […]
Despite more than 200 companies worldwide actively developing microbiome-based therapeutics, both the pre-clinical and clinical development of these drug products is fraught with uncertainty. Data generated from R&D activities on a microbiome-related drug product are […]
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today an exclusive license agreement and research collaboration with Takeda Pharmaceutical Company Limited (Takeda) to develop novel microbiome therapeutics for the treatment of gastrointestinal (GI) disorders. The preclinical program […]